ストックスクリーナーアプリを入手
25.83
2.01%
0.51
アフターアワーズ：
26.05
0.22
+0.85%
Ultragenyx Pharmaceutical Inc (RARE) 最新ニュース
RARE Stock Clocks Two Consecutive Days Of Losses Ahead Of Weekend FDA Decision On Gene Therapy - Stocktwits
Ultragenyx: Progress Is Real, But Profitability Is The Real Test (Rating Upgrade) - Seeking Alpha
RARE Maintained by Morgan Stanley -- Price Target Raised to $74 - GuruFocus
Moderna and Merck’s cancer vaccine clears phase 3; Ultragenyx lands gene therapy nod - Pharma Voice
Morgan Stanley Issues Positive Forecast for Ultragenyx Pharmaceutical (NASDAQ:RARE) Stock Price - MarketBeat
How Investors May Respond To Ultragenyx Pharmaceutical (RARE) First FDA Accelerated Approval For GENGLYCOS - simplywall.st
182,638 Shares in Ultragenyx Pharmaceutical Inc. $RARE Purchased by Blue Owl Capital Holdings LP - MarketBeat
RTW INVESTMENTS, LP Buys Ultragenyx Pharmaceutical Inc (RARE) -- Shares Look 44% Undervalued on GF Value - GuruFocus
RARE Maintained by Canaccord Genuity -- Price Target Raised to $83 - GuruFocus
Canaccord Genuity Group Forecasts Strong Price Appreciation for Ultragenyx Pharmaceutical (NASDAQ:RARE) Stock - MarketBeat
Ultragenyx scores FDA approval for gene therapy made at Bedford facility - The Business Journals
RARE Maintained by Citigroup -- Price Target Raised to $58.00 - GuruFocus
Citigroup Raises Ultragenyx Pharmaceutical (NASDAQ:RARE) Price Target to $58.00 - MarketBeat
Ultragenyx Gene Therapy Becomes First FDA-Approved Treatment for Ultra-Rare Disease - MedCity News
Ultragenyx Shares Surge as FDA Grants First-Ever Approval for GSDIa Gene Therapy - finance.biggo.com
GSDIa Gene Therapy Approval Signals New Path for Rare Disease Manufacturing - PharmTech.com
RARE Maintained by Wells Fargo -- Price Target Raised to $46.00 - GuruFocus
Ultragenyx, after setbacks, nabs first gene therapy approval - BioPharma Dive
Ultragenyx Pharmaceutical (NASDAQ:RARE) Given New $46.00 Price Target at Wells Fargo & Company - MarketBeat
FDA Grants Accelerated Approval to Ultragenyx's Genglycos, First Gene Therapy for Glycogen Storage Disease Type Ia - BioPharm International
Ultragenyx Pharmaceutical (NASDAQ:RARE) Shares Gap Up After Analyst Upgrade - MarketBeat
Ultragenyx wins FDA approval for first treatment targeting root cause of GSDIa - pharmaphorum
RARE Stock Gains on FDA Nod for Rare Disease Gene Therapy Genglycos - TradingView
Ultragenyx Lands Genglycos Approval And Sets Its Sights On A PRV Double - insights.citeline.com
Ultragenyx's new therapy targets patients with a rare genetic disease. It costs $2.7 million. - The Business Journals
H.C. Wainwright reiterates Ultragenyx stock rating at buy By Investing.com - Investing.com Nigeria
FDA approves Ultragenyx gene therapy - STAT
Canaccord raises Ultragenyx stock price target on FDA approval By Investing.com - Investing.com South Africa
Ultragenyx’s Gene-Therapy Win Could Unlock A ‘Long Revenue Tailwind,’ Says Wells Fargo — This Analyst Sees 265% Upside For RARE Stock - Yahoo Finance
Ultragenyx Nabs FDA Nod for First Gene TherapyUltragenyx Pharmaceutical (NASDAQ:RARE) - Benzinga
Cantor Fitzgerald Forecasts Strong Price Appreciation for Ultragenyx Pharmaceutical (NASDAQ:RARE) Stock - MarketBeat
H.C. Wainwright reiterates Ultragenyx stock rating at buy - Investing.com
Canaccord raises Ultragenyx stock price target on FDA approval - Investing.com
FDA grants accelerated approval to Ultragenyx’s Genglycos gene therapy - Pharmaceutical Business review -
Ultragenyx Wins FDA Approval for GENGLYCOS, Its First Gene Therapy - MarketBeat
RARE Maintained by Cantor Fitzgerald -- Price Target Raised to $103 - GuruFocus
Ultragenyx’ Genglycos wins FDA accelerated approval - The Pharma Letter
FDA approves Genglycos as first gene therapy for glycogen storage disease type Ia - AllSci
Eagle Health Investments LP Acquires Shares of 884,121 Ultragenyx Pharmaceutical Inc. $RARE - MarketBeat
Ultragenyx's gene therapy wins first FDA approval for rare metabolic disorder - Reuters
Ultragenyx stock surges on FDA gene therapy approval - Investing.com
Ultragenyx’s gene therapy wins first FDA approval for rare metabolic disorder - 101 WIXX
Ultragenyx Earnings Call Signals Record Sales, 2027 Pivot - TipRanks
Ultragenyx gets its first gene therapy over the regulatory finish line - FirstWord Pharma
RARE Stock Jumps 6% After-Hours On First Gene Therapy Approval, New Priority Review Voucher - Stocktwits
Ultragenyx receives FDA approval for gene therapy treating GSDIa By Investing.com - Investing.com Nigeria
Form 8K Ultragenyx For: 19 August By Investing.com - Investing.com South Africa
Ultragenyx stock surges on FDA gene therapy approval By Investing.com - Investing.com Australia
Ultragenyx’s gene therapy for rare metabolic disorder secures US FDA nod - 1470 & 100.3 WMBD
RARE Looks 41.8% Undervalued on GF Value™ After FDA Approval Boo - GuruFocus
Ultragenyx receives FDA accelerated approval for gene therapy in GSDIa By Investing.com - Investing.com Canada
Ultragenyx receives FDA accelerated approval for gene therapy in GSDIa - Investing.com
Ultragenyx Pharmaceutical Receives Accelerated US FDA Approval for Genglycos - marketscreener.com
Ultragenyx wins accelerated approval of gene therapy for glycogen storage disease - Seeking Alpha
Ultragenyx's gene therapy for rare metabolic disorder secures US FDA nod - Yahoo
1.21%
1.07%
大文字化:
|
ボリューム (24 時間):